KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Net Income (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Net Income for 10 consecutive years, with $38.1 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 893.61% to $38.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158000.0 through Dec 2025, up 100.37% year-over-year, with the annual reading at $128000.0 for FY2025, 100.3% up from the prior year.
  • Net Income hit $38.1 million in Q4 2025 for Fulgent Genetics, up from -$6.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $200.7 million in Q1 2021 to a low of -$122.9 million in Q4 2023.
  • Historically, Net Income has averaged $21.9 million across 5 years, with a median of -$7.9 million in 2024.
  • Biggest five-year swings in Net Income: surged 11856.94% in 2021 and later plummeted 1100.74% in 2023.
  • Year by year, Net Income stood at $103.7 million in 2021, then plummeted by 123.22% to -$24.1 million in 2022, then crashed by 410.4% to -$122.9 million in 2023, then soared by 96.09% to -$4.8 million in 2024, then surged by 893.61% to $38.1 million in 2025.
  • Business Quant data shows Net Income for FLGT at $38.1 million in Q4 2025, -$6.8 million in Q3 2025, and -$19.2 million in Q2 2025.